[1]
“PD-L1 Expression as a Predictor of Response to Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer”, J Evid Based Med Res, vol. 2, no. 03, pp. 58–69, Sep. 2026, doi: 10.66687/jebmr.2.03.2026.43.